Double Bond Pharmaceutical (DBP) Q2 2025 earnings summary

Executive summary

• Achieved significant progress in main project S1053, with strong market interest and ongoing partnership discussions.

• Ended partnership with Vivo, enabling new strategic collaborations.

• Accelerated development of pipeline projects, including SA033 for liver cancer and new BeloGal applications.

Financial highlights

• Q2 2025 total revenue was 1.5 MSEK, up from 0.2 MSEK year-over-year.

• Operating result for Q2 improved to -0.4 MSEK from -2.1 MSEK year-over-year.

• Net result for Q2 was -0.4 MSEK, a significant improvement from -4.9 MSEK year-over-year.

• H1 2025 total revenue reached 3.0 MSEK, up from 0.6 MSEK year-over-year.

• H1 2025 net result was -1.5 MSEK, compared to -7.4 MSEK year-over-year.

Outlook and guidance

• Actively pursuing new partnerships for S1053 to maximize value.

• Focused on accelerating other pipeline projects and leveraging a strong team and strategy.